Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol

Inclusion Criteria: * The subject is of age 18\~65, both male and female; * Newly pathologically diagnosed with classical Hodgkin's lymphoma (lymphocyte depletion type, lymphocyte rich type, nodular sclerosing type, and mixed cellularity type), who had not accepted previous treatment; * Had stage IIB, III or IV disease, as assessed by the Ann Arbor classification; * ECOG≤2, life expectancy ≥3 month; * A negative serum pregnancy test required for sexually active women of childbearing potential; * The subject voluntarily gives written informed consent to participate in the study. Exclusion Criteria: * Hematopoietic function: * Leukocyte \<3,500/mm3（3.5×109/L） * Neutrophils \<1,500/mm3（1.5×109/L） * Platelets \<100,000/mm3（100×109/L） * Intolerance to any of the active ingredients and/or excipients in the study medications; * Severe central nervous system disorders and mental illness; * Severe heart disease (congestive heart failure, uncontrolled hypertension, unstable coronary artery disease, or myocardial infarction, or severe arrhythmia). Echocardiography showed resting left ventricular ejection fraction (LVEF) \< 50%); * History of severe lung disease; * AST or ALT\>2.5×ULN，total bilirubin≥1.5×ULN，serum creatinine\>1.5×ULN (for subject with liver metastases: AST or ALT\>5xULN, total bilirubin ≥ 3xULN); * Uncontrolled, systemic, active infection； * Positive serology to HIV; * HBsAg positive subjects can still be enrolled in the study, but researchers should follow "The consensus on the Treatment of Lymphoma with Hepatitis B Infections" to observe closely and/or provide prophylactic anti-HBV therapy (as per investigator's decision); * Other previous or concomitant malignancy, except for basal cell carcinoma and/or cervical carcinoma in situ; * The subject is receiving an investigational drug, or has participated in an investigational study within 30 days prior to screening; * The subject is pregnant or lactating; or subjects of childbearing potential (both women and man subjects) do not want to take effective contraceptive measures during study period or within 3 months after study completes; * Investigators believe subjects not suitable to participate in the study for other reasons.